Clinical Trial Details
| Trial ID: | L6449 |
| Source ID: | NCT00310297 |
| Associated Drug: | Insulin Glulisine |
| Title: | Insulin Glulisine in Type 2 Diabetes Mellitus |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: Insulin Glulisine |
| Outcome Measures: | Primary: Maximum plasma glucose concentration (GLUmax, mmol/L), During the Study Conduct|Maximum plasma glucose excursion (baseline subtracted glucose concentration, ΔGLUmax, mmol/L), during the study conduct|Time to GLUmax (Tmax, min), during the study conduct | Secondary: Area under the insulin concentration-time curve after injection(μIU.min/mL), between 0 h and 1 h (AUC0-1h), 0 h and 1.5 h (AUC0-1.5h), 0 h and 2 h (AUC0-2h) and 0 h and 4 h (AUC0-4h)|Maximum concentration (Cmax, μIU/mL), During the study conduct|Adverse events collection, from the inform consnet signed up to the end of the study|Time to maximum concentration (Tmax, min), During the study conduct |
| Sponsor/Collaborators: | Sponsor: Sanofi |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2004-11 |
| Completion Date: | |
| Results First Posted: | |
| Last Update Posted: | 2011-01-11 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT00310297 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|